First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin

This publication has 12 references indexed in Scilit:

• Exploratory Phase III Study of Paclitaxel and Cisplatin Versus Paclitaxel and Carboplatin in Advanced Ovarian Cancer
  Journal of Clinical Oncology, 2000
• Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results
  JNCI Journal of the National Cancer Institute, 2000
• Cardiotoxicity of Epirubicin/Paclitaxel–Containing Regimens: Role of Cardiac Risk Factors
  Journal of Clinical Oncology, 1999
• First-Line Chemotherapy With Epirubicin, Paclitaxel, and Carboplatin for Advanced Ovarian Cancer: A Phase I/II Study of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group
  Journal of Clinical Oncology, 1999
• Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.
  Journal of Clinical Oncology, 1997
• Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic
  Annals of Oncology, 1996
• Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
  New England Journal of Medicine, 1996
• Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
  Journal of Clinical Oncology, 1995
• Impact of doxorubicin on survival in advanced ovarian cancer.
  Journal of Clinical Oncology, 1995
• Randomized Comparison of Cisplatin plus Epirubicin or Doxorubicin for Advanced Epithelial Ovarian Carcinoma
  American Journal of Clinical Oncology, 1992